Summit Therapeutics is advancing late-stage trials for ivonescimab, a leading PD-1xVEGF bispecific antibody, in lung cancer. However, a growing number of industry experts are questioning the appropriateness of this focus, suggesting that these bispecifics may be more effective in targeting different tumor types. This perspective arises from emerging data indicating that the mechanism of action for PD-1xVEGF bispecifics could be more beneficial in cancers with distinct microenvironments, such as certain solid tumors beyond lung cancer.
The implications of this debate are significant for the biopharma landscape. If these bispecifics prove to be less effective in lung cancer than anticipated, it could lead to a reevaluation of clinical strategies and resource allocation in oncology research. Furthermore, a shift in focus could open new avenues for patient treatment options and impact the competitive positioning of companies involved in bispecific development.
Open the full market picture for your next decision →
